Neurexis Therapeutics, based in Aurora, CO, is a pioneering biotech company dedicated to addressing the significant impact of stroke and cardiac arrest on human health. With a focus on neuroprotective innovation, Neurexis aims to reduce neuronal death and cognitive impairment caused by the loss of blood flow to the brain, offering a promising solution to an unmet medical need.
By developing tatCN19o, an optimized peptide with proven efficacy and safety in animal models, Neurexis Therapeutics is at the forefront of advancing a potential FDA-approved neuroprotective treatment that can greatly improve the quality of life for patients and alleviate the burden on healthcare systems both domestically and internationally.
Generated from the website